Inventory extension at the Nuclear Materials Storage Facility

The planned renovation of the Nuclear Material Storage Facility (NMSF) at Los Alamos National Laboratory will be a significant addition to the plutonium storage capacity of the nuclear weapons complex. However, the utility of the facility may be impaired by an overly conservative approach to performing inventories of material in storage. This report examines options for taking advantage of provisions in Department of Energy orders to extend the time between inventories. These extensions are based on a combination of modern surveillance technology, facility design features, and revised operational procedures. The report also addresses the possibility that NMSF could be the site of some form of international inspection as part of the US arms control and nonproliferation policy

Inventory extension considerations for long-term storage at the nuclear materials storage facility

Los Alamos National Laboratory is in the process of modifying its nuclear materials storage facility to a long-term storage configuration. In support of this effort, we examined technical and administrative means to extend periods between physical inventories. Both the frequency and sample size during a physical inventory could significantly impact required sizing of the non-destructive assay (NDA) laboratory as well as material handling capabilities. Several options are being considered, including (1) treating each storage location as a separate vault, (2) minimizing the number of items returned for quantitative analysis by optimizing the use of in situ confirmatory measurements, and (3) utilizing advanced monitoring technologies. Careful consideration of these parameters should allow us to achieve and demonstrate safe and secure storage while minimizing the impact on facility operations and without having to increase the size of the NDA laboratory beyond that required for anticipated shipping and receiving activities

Resection of the liver for colorectal carcinoma metastases - A multi-institutional study of long-term survivors

In this review of a collected series of patients undergoing hepatic resection for colorectal metastases, 100 patients were found to have survived greater than five years from the time of resection. Of these 100 long-term survivors, 71 remain disease-free through the last follow-up, 19 recurred prior to five years, and ten recurred after five years. Patient characteristics that may have contributed to survival were examined. Procedures performed included five trisegmentectomies, 32 lobectomies, 16 left lateral segmentectomies, and 45 wedge resections. The margin of resection was recorded in 27 patients, one of whom had a positive margin, nine of whom had a less than or equal to 1-cm margin, and 17 of whom had a greater than 1-cm margin. Eighty-one patients had a solitary metastasis to the liver, 11 patients had two metastases, one patient had three metastases, and four patients had four metastases. Thirty patients had Stage C primary carcinoma, 40 had Stage B primary carcinoma, and one had Stage A primarycarcinoma. The disease-free interval from the time of colon resection to the time of liver resection was less than one year in 65 patients, and greater than one year in 34 patients. Three patients had bilobar metastases. Four of the patients had extrahepatic disease resected simultaneously with the liver resection. Though several contraindications to hepatic resection have been proposed in the past, five-year survival has been found in patients with extrahepatic disease resected simultaneously, patients with bilobar metastases, patients with multiple metastases, and patients with positive margins. Five-year disease-free survivors are also present in each of these subsets. It is concluded that five-year survival is possible in the presence of reported contraindications to resection, and therefore that the decision to resect the liver must be individualized. © 1988 American Society of Colon and Rectal Surgeons

Gyrokinetic turbulence: a nonlinear route to dissipation through phase space

This paper describes a conceptual framework for understanding kinetic plasma turbulence as a generalized form of energy cascade in phase space. It is emphasized that conversion of turbulent energy into thermodynamic heat is only achievable in the presence of some (however small) degree of collisionality. The smallness of the collision rate is compensated by the emergence of small-scale structure in the velocity space. For gyrokinetic turbulence, a nonlinear perpendicular phase mixing mechanism is identified and described as a turbulent cascade of entropy fluctuations simultaneously occurring at spatial scales smaller than the ion gyroscale and in velocity space. Scaling relations for the resulting fluctuation spectra are derived. An estimate for the collisional cutoff is provided. The importance of adequately modeling and resolving collisions in gyrokinetic simulations is biefly discussed, as well as the relevance of these results to understanding the dissipation-range turbulence in the solar wind and the electrostatic microturbulence in fusion plasmas.Comment: iop revtex style, 14 pages, 1 figure; submitted to PPCF; invited talk for EPS Conference on Plasma Physics, Crete, June 2008; Replaced to match published versio

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ−), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ− subjects on the ADAS-Cog over 36 months (5.66±1.47 vs −0.71±1.09, P=0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution (DSS) test, and a verbal fluency test (P<0.05). Similar to MCI subjects, Aβ+ CN subjects showed greater decline on the ADAS-Cog, digit-symbol-substitution test and verbal fluency (P<0.05), whereas Aβ+ AD patients showed greater declines in verbal fluency and the MMSE (P<0.05). Aβ+ subjects in all diagnostic groups also showed greater decline on the CDR-SB (P<0.04), a global clinical assessment. Aβ+ subjects did not show significantly greater declines on the ADCS-ADL or Wechsler Memory Scale. Overall, these findings suggest that in CN, MCI and AD subjects, florbetapir PET Aβ+ subjects show greater cognitive and global deterioration over a 3-year follow-up than Aβ− subjects do

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead